Item 1.01 Entry into a Material Definitive Agreement.

Amendment to the Common Stock Purchase Agreement dated September 1, 2022:

As previously reported by United Health Products, Inc. (the "Company") in a Current Report on Form 8-K filed with the Securities and Exchange Commission on September 7, 2022, the Company previously entered into a common stock purchase agreement dated September 1, 2022 (the "CSPA") with White Lion Capital, LLC ("White Lion").

The CSPA originally provided the Company with the right, but not the obligation, to require White Lion to purchase shares of the Company's common stock at a purchase price equal to 93% of the lower of (i) the volume-weighted average price (the "VWAP") of the Company's common stock during a period of five consecutive trading days following the Company's exercise of its right to sell shares, or (ii) the closing price of its common stock on the day the Company exercises its right to sell shares, subject to a minimum price of $0.25 per share (the "Floor Price"). The CSPA also originally provided that the Company may not issue a share purchase notice to White Lion if the Company's common stock is trading below the Floor Price unless White Lion waives the Floor Price condition at its discretion.

On January 25, 2023, the Company and White Lion amended the CSPA to provide that if the Company issues a share price purchase notice at a time that the Company's common stock is trading below the Floor Price and White Lion waives the Floor Price condition, the share purchase price multiplier for that transaction will be 90% instead of 93%.

Except as set forth in the amendment to the CSPA, all other terms, conditions, and provisions of the CSPA, remain in full force and effect.

The foregoing summary of the material terms of the amendment to the CSPA are qualified entirely by reference to the full text of the amendment, a copy of which will be filed with the Company's Annual Report on Form 10-K for the year ended December 31, 2022.




Item 8.01. Other Events.

On January 31, 2023, the Company issued a press release announcing an update on the FDA's Premarket Approval Application for the Company's HemoStyp® Gauze and the amendment to the CSPA with White Lion.

A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit
Number     Description

  99.1       Press release, dated January 31, 2023
104        Cover Page Interactive Data File (embedded within the Inline XBRL
           Document)





2

© Edgar Online, source Glimpses